CEL-SCI Corporation (NYSEAM: CVM)
Health Care · Biotechnology · US
$1.38
-2.82% today · -86.9% 1Y
CEL-SCI Corporation (NYSEAM: CVM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $24.27M and employs 43 people.
Over the last twelve months the share price has lost 86.9%, trading between 0.89 and 13.48.
Tweenvest scores CEL-SCI Corporation across four factors: quality 26/100. Its strongest factor is quality.
CVM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $24.27M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.57
- Dividend yield
- —
- Beta (5Y)
- 0.56
- 52-week high
- $13.48
- 52-week low
- $0.89
- Avg volume (3M)
- —
- Shares outstanding
- 17.59M
- Employees
- 43
- Next earnings
- —
About CEL-SCI Corporation
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
- ISIN
- US1508377066
- Founded
- 1983
- Listed since
- Dec 8, 1983
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.83 | +2.12% |
Figures last refreshed Aug 18, 2026.